Aligos Therapeutics (NASDAQ:ALGS) Issues Quarterly Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) posted its earnings results on Thursday. The company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.29) by $0.08, FiscalAI reports. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The firm had revenue of $2.83 million during the quarter, compared to the consensus estimate of $0.25 million.

Aligos Therapeutics Trading Down 5.3%

Shares of NASDAQ ALGS traded down $0.34 during midday trading on Thursday, reaching $6.03. 87,644 shares of the stock were exchanged, compared to its average volume of 454,505. The company has a market capitalization of $37.33 million, a P/E ratio of -0.70 and a beta of 2.28. Aligos Therapeutics has a 52-week low of $4.20 and a 52-week high of $13.69. The stock has a 50 day moving average price of $7.10 and a 200-day moving average price of $8.16.

Institutional Investors Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP acquired a new stake in shares of Aligos Therapeutics in the third quarter worth approximately $99,000. XTX Topco Ltd acquired a new stake in shares of Aligos Therapeutics in the second quarter worth approximately $100,000. HRT Financial LP acquired a new stake in shares of Aligos Therapeutics in the fourth quarter worth approximately $106,000. DRW Securities LLC acquired a new stake in shares of Aligos Therapeutics in the fourth quarter worth approximately $111,000. Finally, Jane Street Group LLC acquired a new stake in shares of Aligos Therapeutics in the fourth quarter worth approximately $226,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on ALGS shares. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. UBS Group started coverage on shares of Aligos Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $20.00 target price for the company. Finally, Westpark Capital began coverage on shares of Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.